1 month Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics Zacks
NVS expects sales to witness a CAGR of 6% during 2023-2028, up from the earlier projection of 5%. The company acquires Kate Therapeutics to strengthen its portflio of gene therapies.
X